Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors

Laboratory Investigation

Volumn 77, Issue 6, 1997, Pages 607-614

  Sowter, Heidi M ^a,b   Corps, Anthony N ^a   Evans, Amanda L ^a   Clark, Dawn E ^a   Charnock Jones, D Stephen ^a   Smith, Stephen K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Rosie Maternity Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MACROPHAGE; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION;

ADULT; AGED; CARCINOMA; ENDOTHELIAL GROWTH FACTORS; EPITHELIUM; FEMALE; HUMANS; LYMPHOKINES; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031458922     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, and Brown LF (1996). Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74:1105-1115.
2. Birkenhäger R, Schneppe B, Rockl W, Wilting J, Weich HA, and McCarthy JEG (1996). Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J 316:703-707.
3. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, and Smith SK (1995). Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506-516.
4. Breier G and Risau W (1996). The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 6:454-456.
5. Buick RN, Pullano R, and Trent JM (1985). Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45:3668-3676.
6. Cao Y, Chen H, Zhou L, Chiang M-K, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, and Tsang ML-S (1996). Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271:3154-3162.
7. Chomczynski P and Sacchi N (1987). Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
8. Clark DE, Smith SK, Sharkey AM, Sowter HM, and Charnock-Jones DS (1996). Hepatocyte growth factor/scatter factor and its receptor c-met: Localisation and expression in the human placenta throughout pregnancy. J Endocrinol 151: 459-467.
9. DiSalvo J, Bayne ML, Conn GK, Kwok PW, Trivedi PG, Soderman DD, Palesi TM, Sullivan KA, and Thomas KA (1995). Purification of a naturally occurring vascular endothelial growth factor: Placenta growth factor heterodimer. J Biol Chem 270:7717-7723.
10. Ferrara N and Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocr Rev 18:4-25.
11. Grimmond S, Lagercrantz J, Drinkwater C, Silins G, Townson S, Pollock P, Gotley D, Carson E, Rakar S, Nordenskjold M, Ward L, Hayward N, and Weber G (1996). Cloning and characterisation of a novel human gene related to vascular endothelial growth factor. Genome Res 6:124-131.
12. Hauser S and Weich WA (1993). A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9:259-268.
13. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, and Leung DW (1991). The vascular endothelial growth factor family: Identification of a fourth molecular species and characterisation of alternative splicing of RNA. Mol Endocrinol 5:1806-1814.
14. Houck KA, Leung DW, Rowland AM, Winer J, and Ferrara N (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
15. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, and Alitalo K (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298.
16. Lee J, Gray A, Yuan J, Luoh S-M, Avraham H, and Wood WI (1996). Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93:1988-1992.
17. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, and Persico MG (1991). Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271.
18. Maglione D, Guerriero V, Vilietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei K-J, Chou JY, and Persico MG (1993). Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14. Oncogene 8:925-931.
19. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, and Smith SK (1996). Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 98:482-489.
20. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, and Strawn LM (1996). Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615-1620.
21. Minchenko A, Bauer T, Salceda S, and Caro J (1994). Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71:374-379.
22. Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai X-G, Niwa O, Tsujimura T, Sato B, Terano H, Fujiwara H, and Hamaoka T (1996). Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 87:963-971.
23. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, and Eriksson U (1996a). Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576-2581.
24. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, and Eriksson U (1996b). Genomic organisation of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterisation of a second splice isoform. J Biol Chem 271:19310-19317.
25. Olson TA, Mohanraj D, Carson LF, and Ramakrishnan S (1994). Vascular permeability factor gene expression in normal and neoplastic ovaries. Cancer Res 54:276-280.
26. Olson TA, Mohanraj D, and Ramakrishnan S (1996). In vivo neutralisation of vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int J Oncol 8:505-511.
27. Park JE, Chen HH, Winer J, Houck KA, and Ferrara N (1994). Placenta growth factor. J Biol Chem 269:25646-25654.
28. Schweiki D, Itin I, Soffer D, and Keshet E (1992). Vascular endothelial factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
29. Sharkey AM, Dellow K, Blayney M, Macnamee M, Charnock-Jones DS, and Smith SK (1995). Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. Biol Reprod 53:974-981.
30. Silins G, Grimmond S, Egerton M, and Hayward N (1997). Analysis of the promoter region of the human VEGF-related factor gene. Biochem Biophys Res Commun 230:413-418.
31. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, and Sorg C (1994). Macrophages and angiogenesis. J Leukoc Biol 55:410-422.
32. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, and Abraham JA (1991). The human gene for vascular endothelial growth factor. J Biol Chem 266:11947-11954.
33. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincetti V, Granger HJ, Viglietto G, and Persico MG (1997). Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76:517-531.